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Background: Increased values of C-reactive protein
(CRP), the classical acute phase protein, within the
range below 5 mg/L, previously considered to be within
the reference interval, are strongly associated with in-
creased risk of atherothrombotic events, and are clini-
cally significant in osteoarthritis and neonatal infection.
Methods: A robust new polyclonal-monoclonal solid-
phase IRMA for CRP was developed, with a range of
0.05–10.0 mg/L.
Results: Plasma CRP values in general adult popula-
tions from Augsburg, Germany (2291 males and 2203
females; ages, 25–74 years) and Glasgow, Scotland (604
males and 650 females; ages, 25–64 years) were very
similar. The median CRP approximately doubled with
age, from ;1 mg/L in the youngest decade to ;2 mg/L in
the oldest, and tended to be higher in females.
Conclusion: This extensive data set, the largest such
study of CRP, provides valuable reference information
for future clinical and epidemiological investigations.
© 2000 American Association for Clinical Chemistry
Measurement of C-reactive protein (CRP),5 the classical
acute phase protein, is an extremely valuable marker of
disease activity and response to therapy in a wide range
of tissue-damaging, inflammatory, infective, and neoplas-
tic conditions (1 ). The original automated nephelometric
and turbidimetric immunoassays for CRP developed in
the 1970s and the homogeneous enzyme and fluorescence
polarization methods introduced in the early 1980s had
limited sensitivity and poor precision in the low range.
Thus, values below 5–10 mg/L could not be detected,
although later improvements in some systems reduced
the limit of detection to ;2 mg/L. This was not a problem
because the median value for serum CRP in apparently
healthy adults is ;0.8 mg/L, the 90th centile of the
distribution in such subjects is ;3 mg/L, and all the
information required for the classical applications of
clinical CRP measurement in adults derives from in-
creases in CRP concentration above these concentrations
(1, 2). However, the recent use of more sensitive immu-
noassays for CRP has revealed exciting new information
of both fundamental and clinical importance in three
different areas: coronary heart disease and other compli-
cations of atherosclerosis (3–15), osteoarthritis (16 ), and
neonatal infections (17 ).
Although there now are several commercially avail-
able, routine clinical chemistry assays capable of precisely
measuring circulating CRP concentrations within what
was previously considered to be the reference interval,
these were not available when we commenced our studies
(3, 6). We therefore developed, and report here, a sensi-
tive solid-phase monoclonal-polyclonal IRMA designed
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to measure CRP in plasma or serum of all subjects in the
general population (12, 18–21).
Materials and Methods
crp and anti-crp antibodies
CRP was isolated and purified as described previously
(22, 23) and was used to raise monoclonal mouse and
monospecific polyclonal goat anti-human CRP antisera.
Mouse monoclonal anti-CRP antibodies were isolated
from ascitic fluid by sodium sulfate precipitation and
DEAE-Sepharose ion-exchange chromatography. Goat
polyclonal anti-CRP antibodies were isolated by thio-
philic affinity chromatography on a broad spectrum im-
munoglobulin-binding matrix (T-Gel; Bioaffinity Sys-
tems).
immobilization of polyclonal anti-crp
Microtiter plates with N-oxysuccinimide-activated sur-
faces (Corning Costar) were coated with goat anti-CRP
antibodies by incubation with 100 mL per well of the
immunoglobulin fraction at 100 mg/L in phosphate-
buffered saline (PBS), pH 9.0, for 1 h at 21 °C. After
decanting, the wells were each washed twice with 200 mL
of PBS, pH 7.4, containing 0.5 mL/L Tween 20 (Bio-Rad
Laboratories), before blocking for 30 min with 100 mL per
well of 20 g/L bovine serum albumin in PBS, pH 7.4. After
each well underwent a final rinse step (three times with
200-mL volumes of PBS), the plates were used for assays
on the same day.
radiolabeling of monoclonal anti-crp
Isolated monoclonal anti-CRP antibodies were oxida-
tively iodinated using N-bromosuccinimide (24 ) and car-
rier-free Na125I, and after separation by gel filtration on
G25 Sephadex (PD10 column; Pharmacia Biotech AB), the
labeled antibodies had a typical specific activity of 17
kBq/mg.
irma for crp
Calibrators were constructed that contained isolated CRP
at concentrations of 0.05, 0.10, 0.25, 0.50, 1.00, 5.00, and
10.00 mg/L in solution in 0.14 mol/L NaCl, 0.01 mol/L
Tris, 0.002 mol/L CaCl2 (pH 8.0), containing 10 g/L
bovine serum albumin and 2 mL/L Tween 20 (TCBT
buffer). These calibrators, together with serum or plasma
samples for assay and control sera with known CRP
concentrations, were each diluted 1:100 in the same TCBT
buffer but containing CaCl2 at a final concentration of 0.01
mol/L, and were then loaded in triplicate into the anti-
CRP-coated plates at 100 mL per well. The additional
calcium was included to ensure availability of free cal-
cium ions in all samples including EDTA plasma. After
incubation at 37 °C for 1 h, the plates were decanted, and
each well was washed three times with 200 mL of TCBT
buffer. Captured CRP was then detected by addition to
each well of 100 mL of 125I-labeled monoclonal anti-CRP
antibody containing an activity of 100 000 cpm. After
incubation at 37 °C for 1 h, the plates were decanted, and
each well was washed three times with 200 mL of TCBT
buffer before finally being blotted dry and counted indi-
vidually in the gamma counter. The calibration curve was
constructed using a four-parameter logistic curve-fit pro-
gram, and values for samples and controls were deter-
mined by interpolation. All samples with values at the top
of the assay range, i.e., $10 mg/L, were reassayed at
appropriately higher sample dilutions.
assay validation
Intra- and interassay CVs were initially determined in
London using sera from four patients (three pregnant
females and one male with reactive systemic AA amyloid-
osis). Each sample was assayed in quadruplicate in each
of three separate assays conducted within a period of 21
days. Recovery of CRP was tested by adding known
amounts of pure CRP into two separate clinical samples
and then assaying them in quadruplicate in three separate
assays. We looked for correlation between the present
method and an established high-sensitivity CRP immu-
noassay, using 80 serum samples from healthy adult
laboratory staff in whom values had been determined
previously by the method we developed on the Abbott
IMx® instrument (Abbott Laboratories) (25 ). Results were
compared by the Bland-Altman method to establish the
mean difference. Subsequently, the assay was transferred
to Ulm where intra- and interassay CVs were determined
as in London. The results were the same, and the calibra-
tion curves were superimposable and were extended to
confirm complete concordance between standardization
on the purified CRP calibrators and using the WHO
International Reference Standard for CRP Immunoassay,
85/506 (26 ). All of the population samples described
below, as well as the samples in our other published
reports (12, 18–21), were assayed in Ulm. A control
plasma pool created at the start of the study and used in
every assay run in Ulm, gave essentially identical results
over a 3-year period. No differences were observed be-
tween serum and plasma samples taken from the same
venesection.
clinical samples
Plasma samples from 2291 males and 2203 females, ages
25–74 years, collected during 1994–1995 in Augsburg,
Germany, and from 604 males and 650 females, ages
25–64 years, collected during 1994 in Glasgow, Scotland
were assayed in the present IRMA to establish CRP values
in the adult general population. The Augsburg partici-
pants were selected from the general population using a
two-stage, age- and sex-stratified random cluster sam-
pling method. The Glasgow subjects were randomly se-
lected from general practitioners’ lists in North Glasgow
District. All subjects gave informed consent, and all
protocols and collection procedures were approved by the
relevant institutional committees. Nonfasting blood was
collected into Na2/Na4EDTA from the antecubital vein, in
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the sitting position with minimal suction and short-term
occlusion. Plasma was obtained by centrifugation at 3000g
for 15 min and was stored immediately at 270 °C until
used for analysis. All assays were performed in Ulm in a
single continuous batch. The main and interactive effects
of age, sex, and location were sought by classical ANOVA
techniques for unbalanced data, using logn transforma-
tion of CRP values, which greatly improved compliance
with normal theory assumptions. All computations were
performed on a personal computer in Windows NT 4 with
SAS software, Release 6.12.
Results
establishment and validation of the assay
The calibrators yielded a response proportional to the
concentration used between 0.05 and 10 mg/L. There was
no overlap in readings between the 0.05 mg/L calibrator
and the zero control consisting of TCBT buffer alone
without added CRP (P 5 0.01, t-test). The difference
between the mean readings for 0.05 mg/L and for the zero
control exceeded 3 SD of either mean in all assays, and
0.05 mg/L was thus the minimum detectable concentra-
tion in this assay. Readings reached a plateau for samples
containing .10 mg/L, and these were therefore
re-assayed at higher dilution.
The intraassay CVs ranged from 5.6% for the 0.50
mg/L calibrator to 1.4% for the 0.10 mg/L calibrator. The
interassay CVs ranged between 8.0% for the 5.0 mg/L
calibrator and 0.5% for the 0.10 mg/L calibrator. Testing
in quadruplicate, in three separate assays on 3 different
days, of clinical samples with values between 0.10 and
4.40 mg/L in the IRMA and 0.10 and 4.20 mg/L in the
IMx assay gave intraassay CVs of 1.8–6.2% and interassay
CVs of 2.8–11%. When pure CRP was added to two
clinical samples containing 0.10 and 0.60 mg/L, respec-
tively, to increase their concentrations to 0.60 and 1.10
mg/L, respectively, re-assaying yielded mean (SD) recov-
eries of 93% (9.6%) and 101% (12 ).
Sera from 80 apparently healthy adults measured in
the IMx assay and by the IRMA had values of 0.05–8.40
mg/L and 0.05–8.20 mg/L, respectively. Bland-Altman
comparison after log transformation of both data sets
gave a mean difference, expressed as the ratio IRMA/
IMx, of 1.04, with 95% limits of agreement of 0.54 and
2.00, indicating excellent agreement between the two
methods.
crp values in the general population
The results from this extremely large survey (Table 1)
were comparable to those reported previously, with the
distribution very heavily skewed to the right, the median
close to 1 mg/L, and only ;5% of samples containing .10
mg/L.
There was a significant trend to higher CRP values
with increasing age in both locations. ANOVA on logn
CRP for effect of age gave P ,0.0001 for both Augsburg
(ages, 25–74 years) and Glasgow (ages, 25–64 years). For
the Glasgow results, ANOVA on logn CRP was not
significant for either the effect of sex (P 5 0.5248) or for
the interaction of age and sex (P 5 0.3864). However, for
the Augsburg results, ANOVA on logn CRP for the effect
of sex was significant, with females being marginally




Plasma CRP concentration, mg/L
Geometric
mean SD Mean Minimum
Percentile
Maximum1st 2.5th 5th 25th 75th 95th 97.5th 99th
Augsburg M 25–34 433 0.81 3.07 0.75 0.05 0.05 0.08 0.12 0.40 1.70 4.88 7.27 10.72 80.69
35–44 435 1.12 3.10 1.13 0.05 0.07 0.11 0.17 0.54 2.39 6.29 9.16 15.46 112.47
45–54 467 1.40 2.97 1.31 0.07 0.15 0.19 0.28 0.65 2.91 8.51 13.95 18.90 74.53
55–64 492 1.56 2.74 1.50 0.06 0.15 0.23 0.32 0.79 3.01 8.16 12.22 22.25 36.48
65–74 464 2.03 2.76 1.93 0.05 0.23 0.33 0.38 1.06 3.88 9.44 18.47 30.60 46.06
F 25–34 412 1.08 3.77 1.02 0.05 0.05 0.07 0.11 0.48 2.45 8.49 17.18 37.22 49.75
35–44 475 1.13 3.47 1.08 0.05 0.06 0.10 0.17 0.46 2.66 8.57 14.86 22.29 34.64
45–54 477 1.29 3.14 1.33 0.08 0.11 0.15 0.20 0.56 2.85 7.92 12.12 25.06 92.81
55–64 470 1.83 2.75 1.76 0.10 0.15 0.25 0.35 0.98 3.66 8.97 10.97 25.34 78.19
65–74 369 2.18 2.66 2.22 0.05 0.21 0.30 0.43 1.20 4.05 9.86 16.58 27.84 52.19
Glasgow M 25–34 144 1.01 2.97 1.01 0.06 0.18 0.20 0.25 0.42 2.14 5.93 8.36 19.50 25.44
35–44 158 1.18 3.24 0.96 0.05 0.06 0.10 0.17 0.58 2.59 7.36 15.78 23.85 25.86
45–54 147 1.54 2.70 1.34 0.15 0.24 0.28 0.36 0.78 2.89 7.82 21.81 31.01 32.26
55–64 155 2.14 2.81 1.96 0.27 0.28 0.29 0.38 1.07 4.33 10.59 20.01 23.55 39.97
F 25–34 177 1.25 3.26 1.33 0.05 0.11 0.12 0.19 0.55 3.23 7.75 10.03 20.34 30.21
35–44 162 1.12 3.10 0.95 0.08 0.12 0.16 0.22 0.49 2.79 7.34 8.95 13.54 20.13
45–54 153 1.46 3.24 1.53 0.09 0.13 0.17 0.22 0.68 3.24 8.85 15.47 18.03 20.75
55–64 158 2.25 3.26 2.40 0.05 0.08 0.15 0.31 1.02 5.27 15.50 24.26 36.31 76.48
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higher (P 5 0.0067), and the interaction of age and sex was
also significant (P 5 0.0084), which complicates interpre-
tation of the main effects. To compare CRP values in the
different locations, the Augsburg 65–74 age group was
eliminated, and full factorial ANOVA of location-sex-age
gave nonsignificant three-factor and two-factor interac-
tions that included location. This permitted interpretation
of the main location effect, which was significant (P
,0.0001) and corresponded to a Glasgow:Augsburg ratio
of 1.16:1 on the back-transformed scale.
Discussion
The present IRMA for CRP, performed in two different
laboratories in different countries and with several differ-
ent operators, gave the same ranges of intra- and interas-
say CVs for all of the calibrators and consistently yielded
the same value for a control plasma pool over a period of
3 years. It was sufficiently sensitive to detect CRP in all
clinical samples tested and has already provided impor-
tant new clinical and scientific information (12, 18–21).
Results obtained by the IRMA for ostensibly healthy
subjects closely matched those from the solid-phase mi-
croparticle-enhanced enzyme immunoassay that we de-
veloped on the Abbott IMx instrument (25 ), and those in
turn were the same as in our early radioimmunoassay
study of CRP concentrations in sera from 469 volunteer
blood donors (2 ). The assays were all standardized on the
same highly purified human CRP preparations that we
used to construct the WHO International Reference Stan-
dard for CRP Immunoassay (85/506) (26 ) and provided
for IFCC Certified Reference Material 470 (27 ). The ex-
pected close agreement of results confirms the specificity
and precision of these methods.
The present study of individuals from the general
population, all measured in a single continuous batch in a
single laboratory, is by far the largest yet reported and
provides robust reference information as well as showing
several features of interest. The usual distribution of CRP
values was found, heavily skewed to the right, and was
similar in men and women and in the Glasgow and
Augsburg populations, although the Glasgow concentra-
tions were slightly higher than those in Augsburg and the
German women had marginally higher concentrations
than the German men. The sex difference may reflect the
estrogen effect we have reported elsewhere (21 ).
The median values, ranging from 0.75 to 2.40 mg/L in
different age groups, were with just one exception higher
than the 0.8 mg/L we reported in our early study of
healthy volunteer blood donors (2 ). The 90th, 95th, and
99th percentiles were also higher. This probably reflects
the existence of more subclinical disease in the general
population than among those accepted as donors by the
United Kingdom National Blood Transfusion Service.
Similar higher CRP values have been reported in previ-
ous, smaller studies of general populations [for example,
see Refs. (13, 15)]. We currently have no explanation for
the higher values found in females in Augsburg but not in
Glasgow, or for the higher values in Glasgow than in
Augsburg, but it is unlikely to result from sample han-
dling. All samples were collected and stored identically.
Using a variety of different in-house (2, 17, 25, 28) and
commercial assays (Abbott, Beckman, Technicon, and
Roche), we have periodically remeasured CRP concentra-
tions in aliquots of normal serum, acute phase serum,
normal and acute phase plasma, and normal serum sup-
plemented with various concentrations of purified CRP
that have been stored frozen at 270 °C for .20 years, and
found no significant change with time (M.B. Pepys, per-
sonal observation). The notable stability of CRP in serum
was also documented in our preparation of WHO Stan-
dard 85/506 (26 ).
Although no specific exclusions were imposed in the
present study, subjects with known acute active disease
were presumably not bled. However, the top 10% or so of
CRP values reflect ongoing acute phase responses at the
time of sampling, presumably resulting from chronic or
low-grade intercurrent infection, inflammation, or other
tissue-damaging processes. The increasing prevalence of
clinical and subclinical diseases that induce an acute
phase response may also underlie the modest, although
statistically significant, increase in median CRP concen-
trations over the decades of age sampled in the present
large number of subjects.
Other possible influences on the relationship between
age and plasma CRP concentration are smoking and
obesity (13 ). CRP concentrations are known to be affected
by smoking, presumably through its inflammatory and
tissue-damaging effects and the smoker’s increased sus-
ceptibility to respiratory infection. Obesity is associated
with increased CRP concentrations, presumably because
adipose tissue is an important site for production of
interleukin-6, the major up-regulator of CRP gene expres-
sion (29 ). CRP values are also associated with compo-
nents of the insulin-resistance syndrome (30 ); however, at
present, we lack the information required to investigate
such associations in the populations studied here.
The strongly predictive association between increased
CRP concentrations and coronary heart disease, ischemic
stroke, and peripheral arterial disease is of particular
interest and importance (3–13). It has emerged from
studies in which individuals known to have diseases
capable of inducing an acute phase response have been
excluded, and it is observed even at very modestly
increased CRP values. However, it is not known whether
the increased CRP production reflects the extent of ath-
erosclerosis itself and inflammatory activity within the
plaques, inflammation elsewhere in the body, or just
genetically determined higher baseline CRP concentra-
tions (31 ). It is also not known whether CRP itself
contributes to the pathogenesis of atheroma and its
thrombotic complications or is just a sensitive marker for
underlying inflammation and/or tissue-damaging pro-
cesses that promote atherothrombosis by other mecha-
nisms. These questions will probably be answered only by
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studies with drugs capable of specifically inhibiting the
production or binding and effects of CRP, and such agents
have yet to be developed (32 ). Nevertheless, if increased
CRP production is triggered by the presence, severity, and
extent of atheroma, then these factors may contribute to
the age-related increase in CRP values.
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